



I hereby certify that this correspondence is  
being deposited with the United States  
Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents,  
Washington, D.C. 20231,

On November 8, 2002

By Silvia F. Mauzer

Attorney Docket No. 0228us410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

**Poul Baad Rasmussen, et al.**

Application No.: **10/084,706**

Filed: **February 26, 2002**

For: **Interferon Beta-Like Molecules**

Examiner: **J. Seharaseyon**

Art Unit: **1647**

**RECEIVED**

NOV 15 2002

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 and § 1.98**


TECH CENTER 1600 2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on the attached Forms PTO/SB/08A-B are being called to the attention of the Examiner, to make of record references cited in parent application USSN 09/648,569 filed August 25, 2000. Pursuant to 37 CFR § 1.98(d), copies of the references cited in parent application USSN 09/648,569 are not provided. However, Applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the information cited on the previously submitted Forms PTO/SB/08A-B for parent application USSN 09/648,569 be expressly considered during the prosecution of the present application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.



Application No.: 10/084,706  
Filed: February 26, 2002  
Page 2 of 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

It is believed that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Joanne R. Petithory".

Joanne R. Petithory  
Reg. No. 42,995

Dated: Nov. 8, 2002

Maxygen, Inc.  
Patent Department  
515 Galveston Drive  
Redwood City, California 94063  
Telephone: (650) 298-5300  
Facsimile: (650) 298-5446  
Customer No. 30560



Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/648,569- 10/084, 706
		Filing Date	August 25, 2000 Feb 26, 2002
		First Named Inventor	A. H. Pedersen Rasmussen, P.B.
		Group Art Unit	1647
		Examiner Name	J. Seharaseyoon
		Attorney Docket Number	0202us810 0228us 410


U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
1	5,206,344			Katre et al.	04/27/1993
2	5,738,846			Greenwald et al.	04/14/1998

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T
		Office	Number	Kind Code (if known)		
3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990	
4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93	X RECEIVED
5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93	NOV 15 2002
6	WO	95/27502	A1	Research Development Foundation	10/19/1995	
7	WO	98/35026	A1	Novo Nordisk A/S	08/13/1998	
8	WO	99/55377	A2	Applied Research Systems	11/04/1999	

OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T				
9		Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.				
10		Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/648,569 10/084,706
		Filing Date	August 25, 2000 02/26/02
		First Named Inventor	Anders Hjelholt Pedersen Rasmussen
		Group Art Unit	1633 1647
		Examiner Name	Unassigned J. Seharaseyoun
		Attorney Docket Number	21-107000US 0228US410

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
AA	4,588,585			Mark et al.	05-13-1986
AB	4,686,191			Itoh et al.	08-11-1987
AC	4,769,233			Bell et al.	09-06-1988
AD	4,904,584			Shaw	02-27-1990
AE	4,914,033			Bell et al.	04-03-1990
AF	4,917,888			Katre et al.	04-17-1990
AG	4,966,843			McCormick et al.	10-30-1990
AH	5,218,092			Sasaki et al.	08-06-1993
AI	5,376,567			McCormick et al.	12-27-1994
AJ	5,382,657			Hoffmann-La Roche Inc.	01-17-1995
AK	5,545,723			Goelz et al.	08-13-1996
AL	5,795,779			McCormick et al.	08-18-1998

RECEIVED

NOV 15 2002  
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
AM	WO	95/25170			Biogen, Inc.	09-21-1995
AN	WO	98/48018			Fraun-Hofer-Gesellschaft Zur Forderung Der Angewandten	10-29-1998
AO	WO	99/03887			Bolder Biotechnology	01-28-1999
AP	WO	99/55377			Applied Research	11-04-1999
AQ	WO	99/67291			Immunex Corporation	12-29-1999
AR	WO	00/23114			Biogen, Inc.	04-27-2000

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**COPY FROM PARENT**

Institute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/648,569- 10/084,706
Filing Date	August 25, 2000 02/26/02
First Named Inventor	Anders Hjelholt Pedersen Rasmussen
Group Art Unit	1633- 7647
Examiner Name	Unassigned J. Seharaseyom
Attorney Docket Number	31-107600US- 0228 US 410

	AS	WO	00/23472		Biogen, Inc.	04-27-2000		
	AT	WO	00/26354		Novo Nordisk	05-11-2000		
	AU	EP	083 069		Kyowa Hakko Kogyo Co., Ltd.	09-16-1987		
	AV	EP	041 313		Biogen, Inc.	09-12-1990		<b>RECEIVED</b>
	AW	EP	229 108		Cetus Corporation	12-27-1990	NOV 15 2002	
	AX	EP	260 350		Cetus Corporation	02-12-1992		TECH CENTER 1600/2900
	AY	EP	287 075		Arzneimittelforschung /Drug Research	01-18-1995		
	AZ	EP	539 300		Philippe Thiriet	02-07-1996		
	BA	EP	593 868		Hoffmann-La Roche Inc.	04-15-1998		

OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	BB	Fierlbeck et al., "Neutralising interferon $\beta$ antibodies in melanoma patients treated with recombinant and natural interferon $\beta$ " <u>Cancer Immunol Immunother</u> (1994) 39:263-268	
	BC	Karpusas et al., "The Structure of Human Interferon- $\beta$ : Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
	BD	Karpusas et al. "The crystal structure of human interferon $\beta$ at 2.2 A resolution" <u>Proc. Nat. Acad. Sci. USA</u> (1997) 94:11813-11818	
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" <u>Int. Arch. Allery Immunol</u> 1999; 118:368-371	
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" <u>Clinical Therapeutics</u> vol. 19, No. 5, 1997 883-893	
	BG	Redlich et al., "Antibodies that neutralize human $\beta$ interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <u>Proc. Natl. Acad. Sci. USA</u> vol. 88, pp. 4040-4044 May 1991	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Complete if Known
		Application Number <b>09/648,569- 10/084,706</b>
		Filing Date <b>August 25, 2000 02/26/02</b>
		First Named Inventor <b>Andere, Hjelholt-Pedersen Rasmussen</b>
		Group Art Unit <b>1633 1647</b>
		Examiner Name <b>Unassigned J. Sehavaseyon</b>
		Attorney Docket Number <b>31-107600US- 0228US410</b>

	BH	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" <u>Neurology</u> May 1889, 50: 1266-1272	
	BI	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- $\beta$ (IFN- $\beta$ ) <u>Pharmaceutical Research</u> vol. 15, No 4, 1998, 641-649	
	BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between $\alpha$ and $\beta$ Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008	
	BK	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- $\beta$ at 2.15 A Resolution" <u>J. Mil. Biol.</u> (1995) 253, 187-207	
	BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- $\beta$ : Construction, Expression in <i>E. coli</i> , and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128	
	BM	Taniguchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" <u>Gene</u> 10 (1980) 11-15	
	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" <u>Neurology</u> 1998; 51: 682-689	

RECEIVED  
NOV 15 2002  
TECH CENTER 1600/290C

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.